Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection

Mijnes, Jolein; Tiedemann, Janina; Eschenbruch, Julian; Gasthaus, Janina; Bringezu, Sarah; Bauerschlag, Dirk; Maass, Nicolaì; Arnold, Norbert; Weimer, Jörg; Anzeneder, Tobias; Fasching, Peter A.; Rübner, Matthias; Bruno, Benjamin; Heindrichs, U.; Freres, Jennifer; Schulz, H.; Hilgers, Ralf‐Dieter; Ortiz-Brüchle, Nadina; Serenyi, Sonja von; Knüchel, Ruth; Kloten, Vera; Dahl, Edgar

doi:10.18632/oncotarget.27685

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In bladder carcinogenesis, we previously demonstrated epigenetic inactivation of ITIH5 associated with advanced tumor stages predicting unfavorable prognosis of patients diagnosed with a papillary (pT1) urothelial high-grade tumor [ 20 ]. ITIH5 promoter methylation was also characterized as putative biomarker for non-invasive detection of breast [ 23 ] and bladder cancer [ 24 ] via plasma and urine samples, respectively.…”

Section: Introductionmentioning

confidence: 99%

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells

Rose

Noetzel

Kistermann

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

This study aims at characterizing the role of the putative tumor suppressor ITIH5 in basal-type bladder cancers (BLCA). By sub-classifying TCGA BLCA data, we revealed predominant loss of ITIH5 expression in the basal/squamous-like (BASQ) subtype. ITIH5 expression inversely correlated with basal-type makers such as KRT6A and CD44. Interestingly, Kaplan–Meier analyses showed longer recurrence-free survival in combination with strong CD44 expression, which is thought to mediate ITIH-hyaluronan (HA) binding functions. In vitro, stable ITIH5 overexpression in two basal-type BLCA cell lines showing differential CD44 expression levels, i.e., with (SCaBER) and without squamous features (HT1376), demonstrated clear inhibition of cell and colony growth of BASQ-type SCaBER cells. ITIH5 further enhanced HA-associated cell-matrix attachment, indicated by altered size and number of focal adhesion sites resulting in reduced cell migration capacities. Transcriptomic analyses revealed enrichment of pathways and processes involved in ECM organization, differentiation and cell signaling. Finally, we provide evidence that ITIH5 increase sensitivity of SCaBER cells to chemotherapeutical agents (cisplatin and gemcitabine), whereas responsiveness of HT1376 cells was not affected by ITIH5 expression. Thus, we gain further insights into the putative role of ITIH5 as tumor suppressor highlighting an impact on drug response potentially via the HA-CD44 axis in BASQ-type BLCA.

show abstract

Section: Introductionmentioning

confidence: 99%

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells

Rose

Noetzel

Kistermann

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is widely thought that SPAG6 plays crucial promoting roles in malignancy, as indicated by numerous experiments and clinical studies 20–22 . Nevertheless, an increasing body of evidence suggests that SPAG6 also exerts tumor suppressor effects under specific conditions 14–17 . Notably, the expression levels of SPAG6 in hematological malignancies have been reported to be upregulated compared with common types of solid tumors 18–21 .…”

Section: Discussionmentioning

confidence: 99%

“… 20 , 21 , 22 Nevertheless, an increasing body of evidence suggests that SPAG6 also exerts tumor suppressor effects under specific conditions. 14 , 15 , 16 , 17 Notably, the expression levels of SPAG6 in hematological malignancies have been reported to be upregulated compared with common types of solid tumors. 18 , 19 , 20 , 21 Our previous studies on various leukemia cell lines showed that SPAG6 promoted the growth of hematologic malignant cells by affecting different signaling pathways and connoted with the worse clinical prognosis of MDS and AML patients.…”

Section: Discussionmentioning

confidence: 99%

“…Mammalian SPAG6 was initially identified as a cancer-testis antigen 13 and subsequently found to act as an oncogene or tumor suppressor in human cancers. Some studies have indicated that the promoter of SPAG6 genes is methylated in bladder, lung, and breast cancers and neuroblastoma cell lines, [14][15][16][17] resulting in gene silencing.…”

Section: Introductionmentioning

confidence: 99%

“…Mammalian SPAG6 was initially identified as a cancer‐testis antigen 13 and subsequently found to act as an oncogene or tumor suppressor in human cancers. Some studies have indicated that the promoter of SPAG6 genes is methylated in bladder, lung, and breast cancers and neuroblastoma cell lines, 14 , 15 , 16 , 17 resulting in gene silencing. In contrast, the expression levels of SPAG6 in hematological malignancies MDS, 18 MPN, 19 lymphoma, 20 and AML 21 have been reported to be upregulated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Upregulated SPAG6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon‐α response in BCR::ABL1 negative myeloproliferative neoplasms

Ding,

Luo,

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Sperm‐associated antigen 6 (SPAG6) has been identified as an oncogene or tumor suppressor in various types of human cancer. However, the role of SPAG6 in BCR::ABL1 negative myeloproliferative neoplasms (MPNs) remains unclear. Herein, we found that SPAG6 was upregulated at the mRNA level in primary MPN cells and MPN‐derived leukemia cell lines. The SPAG6 protein was primarily located in the cytoplasm around the nucleus and positively correlated with β‐tubulin expression. In vitro, forced expression of SPAG6 increased cell clone formation and promoted G1 to S cell cycle progression. Downregulation of SPAG6 promoted apoptosis, reduced G1 to S phase transition, and impaired cell proliferation and cytokine release accompanied by downregulated signal transducer and activator of transcription 1 (STAT1) expression. Furthermore, the inhibitory effect of interferon‐α (INF‐α) on the primary MPN cells with high SPAG6 expression was decreased. Downregulation of SPAG6 enhanced STAT1 induction, thus enhancing the proapoptotic and cell cycle arrest effects of INF‐α both in vitro and in vivo. Finally, a decrease in SPAG6 protein expression was noted when the STAT1 signaling was blocked. Chromatin immunoprecipitation assays indicated that STAT1 protein could bind to the SPAG6 promoter, while the dual‐luciferase reporter assay indicated that STAT1 could promote the expression of SPAG6. Our results substantiate the relationship between upregulated SPAG6, increased STAT1, and reduced sensitivity to INF‐α response in MPN.

show abstract

Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection

Cited by 2 publications

References 0 publications

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells

Upregulated SPAG6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon‐α response in BCR::ABL1 negative myeloproliferative neoplasms

Contact Info

Product

Resources

About